How to Join This Clinical Trial - NCTNCT04994717

Learn how to participate in this PHASE3 trial studying an investigational therapy for Newly Diagnosed Philadelphia (Ph)-Negative B-cell Precursor Acute Lymphoblastic Leukemia (ALL). This study is currently enrolling participants.

Am I Eligible for This Clinical Trial?

This clinical research study is looking for participants with Newly Diagnosed Philadelphia (Ph)-Negative B-cell Precursor Acute Lymphoblastic Leukemia (ALL). Eligibility requirements include specific age ranges, health status, and medical history. Contact the study team to learn if you qualify.

Condition Being Studied

Newly Diagnosed Philadelphia (Ph)-Negative B-cell Precursor Acute Lymphoblastic Leukemia (ALL)

Treatment Being Tested

Investigational treatment

Study Phase

PHASE3 - Large-scale efficacy study

Enrollment Status

Currently enrolling participants

Study Identifier

NCTNCT04994717 - ClinicalTrials.gov Identifier

Sponsored By

Study sponsor

What to Expect as a Participant

Participating in this clinical trial involves:

• Initial screening to determine eligibility
• Regular study visits and health assessments
• Receiving the study treatment or placebo
• Medical monitoring and follow-up care
• Contributing to medical research that may help others
• Potential access to new treatments before they're widely available

Clinical Trial Benefits and Compensation

Participants in this clinical research study may receive:

• Close medical monitoring by healthcare professionals
• Access to potential new treatments
• Compensation for time and travel (varies by study)
• No-cost study-related medical care
• The opportunity to help advance medical knowledge

Where Is This Clinical Trial Located?

This study is enrolling participants at 185 locations. Find a study site near you:

And 175 more locations available. Contact us to find the nearest participating site.

How to Enroll in This Study

To learn more about participating in this PHASE3 clinical trial for Newly Diagnosed Philadelphia (Ph)-Negative B-cell Precursor Acute Lymphoblastic Leukemia (ALL):

1. Review the eligibility criteria with your healthcare provider
2. Contact the study team for a pre-screening interview
3. Schedule an in-person screening visit if eligible
4. Review and sign the informed consent form
5. Begin participation in the clinical trial

Why Choose Quri.ai Study Finder

Quri.ai's Study Finder is the leading clinical trial business intelligence platform, helping BD professionals:

• Discover clinical trials before competitors
• Access exclusive contact information
• Track sponsor pipelines and opportunities
• Connect with decision makers directly
• Win more business partnerships